Clinical Trials on Respiratory Syncytial Virus, Congenital Heart Disease in United Kingdom

Total 6809 results

Abbott

Completed

Retrospective Palivizumab Study in Children With Hemodynamically Significant Congenital Heart Disease

Severe Respiratory Syncytial Virus Infection

Austria, Belgium, France, Germany, Italy, Norway, Poland, Slovenia, Spain, United Kingdom
University of Oxford
Innovative Medicines Initiative; Respiratory syncytial virus consortium in...

Active, not recruiting

Understanding RSV: Severe Disease and the Long Term Consequences

Respiratory Syncytial Virus (RSV)

United Kingdom
Pfizer

Completed

Safety, Pharmacokinetics,and Antiviral Activity of RV299 Against Respiratory Syncytical Virus (RSV)

Respiratory Syncytial Virus (RSV)

United Kingdom
Merck Sharp & Dohme LLC

Completed

Phase 2a Respiratory Syncytial Virus (RSV) Human Challenge Study of Clesrovimab (MK-1654) in Healthy Participants (MK-1654-005)

Respiratory Syncytial Viruses

United Kingdom
Merck Sharp & Dohme LLC

Completed

Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017)

Respiratory Syncytial Virus

United Kingdom
Biota Pharma Europe Limited

Completed

Safety, Efficacy and Pharmacokinetics of BTA-C585 in a RSV Viral Challenge Study

Respiratory Syncytial Virus (RSV) Infection

United Kingdom
GlaxoSmithKline

Completed

A Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' RSV Investigational Vaccine (ChAd155-RSV) (GSK3389245A) in Healthy Adults

Respiratory Synctial Virus Infections

United Kingdom
University Hospital Southampton NHS Foundation...
University Hospitals Bristol and Weston NHS Foundation Trust; Oxford University... and other collaborators

Unknown

Respiratory Syncytial Virus (RSV) and Vaccination in Pregnancy

Respiratory Syncytial Virus (RSV) | Attitude | Maternal Vaccine Exposure

United Kingdom
Mucosis BV
Imperial College London

Unknown

Phase I Study for SynGEM, an Intranasal Respiratory Syncytial Virus (RSV) Prefusion F Subunit Candidate Vaccine (SynGEM)

Respiratory Syncytial Viral Infections

United Kingdom
Pfizer

Completed

Pharmacokinetics and Safety of RV521 Formulations (C19007)

Respiratory Syncytial Virus Infections

United Kingdom
Pfizer

Completed

A Study to Learn About the Drug-drug Interactions of Sisunatovir in Healthy Adult Participants

Respiratory Syncytial Virus Infections

United Kingdom
Hvivo
Pfizer

Completed

Study of RSVpreF Vaccination and RSV Challenge in Healthy Adults

Respiratory Syncytial Virus Infections

United Kingdom
University of Oxford

Completed

RSV Observational Study 2

Respiratory Syncytial Virus Infections

United Kingdom
Alios Biopharma Inc.

Completed

A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176

Respiratory Syncytial Virus Infections

United Kingdom
Gilead Sciences

Completed

Safety and Efficacy Study of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV) (Challenge)

Respiratory Syncytial Virus Infections

United Kingdom
Respivert Ltd

Completed

RV568 - Viral Challenge With RSV

Respiratory Syncytial Virus Infections

United Kingdom
Alios Biopharma Inc.

Completed

A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model

Respiratory Syncytial Virus Infections

United Kingdom
Pulmocide Ltd

Completed

A Study of PC786 to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of Multiple Doses in an RSV Challenge Study

Respiratory Syncytial Virus Infections

United Kingdom
Janssen Vaccines & Prevention B.V.

Completed

An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old Adults

Healthy

United Kingdom
ReiThera Srl

Completed

RSV001 - A New Vaccine to Prevent Severe Viral Chest Infections.

Respiratory Syncytial Virus Infections

United Kingdom
Pulmocide Ltd

Completed

A Study to Investigate the Safety and Tolerability of Single and Repeat Doses of PC786

Respiratory Syncytial Virus (RSV)

United Kingdom
MedImmune LLC

Terminated

Intranasal Challenge of Healthy Adults With Respiratory Syncytial Virus (RSV)

RSV Infection

United Kingdom
Imperial College London

Recruiting

The Impact of Age on Adaptive Immunity in Adults Infected With Respiratory Syncytial Virus (INFLAMMAGE)

RSV Infection

United Kingdom
Bavarian Nordic

Completed

Phase 2a Study of MVA-BN-RSV Vaccination and RSV Challenge in Healthy Adults

RSV Infection

United Kingdom
Meissa Vaccines, Inc.
Hvivo

Completed

Human Challenge Study to Evaluate the Efficacy of MV-012-968 Vaccine

RSV Infection

United Kingdom
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age

Respiratory Syncytial Virus

Canada, United Kingdom, Spain, Brazil, Sweden, Poland, Australia, Finland
Pfizer

Completed

Safety, Tolerability, Pharmacokinetics, and Food Effect Study of RV299 in Healthy Adults

Respiratory Syncytial Virus Infections

United Kingdom
Enanta Pharmaceuticals, Inc
hVIVO Services Limited

Completed

A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model

RSV Infection

United Kingdom
Hvivo
GlaxoSmithKline

Completed

RSV Study in Adults 60 to 75 Years of Age

RSV Infection

United Kingdom
Imperial College London
Medical Research Council; Wellcome Trust; National Institute for Health Research...

Terminated

A Study of Protective Immunity Against RSV and Influenza in Experimental Human Challenge of Volunteers

Influenza, Human | Respiratory Syncytial Virus Infections

United Kingdom
Janssen Sciences Ireland UC

Completed

Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection.

Respiratory Syncytial Virus Infections

United Kingdom
Arrow Therapeutics

Completed

A Study of the Safety and Efficacy of A-60444 in Adults With Respiratory Syncytial Virus (RSV) Infection Following HSCT

Respiratory Syncytial Virus Infections

United Kingdom
Imperial College London
Wellcome Trust

Completed

The Development of a Human Model of Respiratory Syncytial Virus Infection

Respiratory Syncytial Virus Infections | Respiratory Viral Infections

United Kingdom
Pfizer

Completed

A Study to Learn About the Effects of Multiple Doses of Sisunatovir on People With Respiratory Syncytial Virus (RSV) Infection

Respiratory Syncytial Virus Infections

United Kingdom
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older

Respiratory Syncytial Virus Immunization

United States, Australia, Puerto Rico
University of Rochester

Completed

Molecular and Microbiome/Metagenome Correlates of Recurrent Wheeze in RSV Infected Infants

Respiratory Syncytial Virus Infection

United States
Enanta Pharmaceuticals, Inc
hVIVO Services Limited

Recruiting

A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model

RSV Infection

United Kingdom
Janssen Research & Development, LLC

Completed

A Two-Part Infant Study for Early Diagnosis of Respiratory Syncytial Virus (RSV) and Evaluation of JNJ-53718678 in RSV Acute Respiratory Tract Disease

Respiratory Syncytial Viruses

Taiwan, Belgium, United Kingdom, Argentina, Panama
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA)

Respiratory Syncytial Virus Infection

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...

Completed

Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults

Respiratory Syncytial Virus

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults

Respiratory Syncytial Virus Infection | Antiviral Prophylaxis

United States
MedImmune LLC

Completed

MEDI-557 Adult Dosing (CD-1092)

Respiratory Syncytial Virus

United States
University of Oxford

Active, not recruiting

RESCEU: Defining the Burden of RSV Disease

Respiratory Syncytial Virus Infections | RSV Infection

United Kingdom
Sanofi Pasteur, a Sanofi Company

Recruiting

BEYFORTUS™ (Nirsevimab) Effectiveness Against Medically-Attended RSV Events in Infants (BEAR Study) (BEAR)

Respiratory Syncytial Virus

United States
Gilead Sciences

Completed

Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection

Respiratory Syncytial Virus Infection

Korea, Republic of, Australia, Israel, New Zealand, Netherlands, United States, France, United Kingdom, Italy, Belgium, Poland
Vaxart

Completed

Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)

Respiratory Syncytial Virus (RSV)

United States
National Institute of Allergy and Infectious Diseases...

Completed

Prevention of RSV Infections in Bone Marrow Transplant Recipients

Respiratory Syncytial Virus Infection

United States
Enanta Pharmaceuticals, Inc

Completed

Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects

Respiratory Syncytial Virus (RSV)

United States
University of Rochester

Active, not recruiting

Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF)

Respiratory Syncytial Virus (RSV)

United States
ModernaTX, Inc.

Recruiting

A Study to Investigate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in High-risk Adults

Respiratory Syncytial Virus

Canada, United States, United Kingdom, Puerto Rico

Clinical Trials on Respiratory Syncytial Virus, Congenital Heart Disease in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations